Navigation Links
RPS Enhances Clinical Expertise and Leadership with Two Additions to Senior Management Team

FORT WASHINGTON, Pa., May 14 /PRNewswire/ -- RPS, Inc. today announced the addition of two new members to its Senior Management Team. David A. Green, Ph.D. joins RPS as Vice President of Clinical Operations. Neil H. Shusterman, M.D. joins RPS as Senior Vice President, Medical, Regulatory and Drug Safety.

"We are pleased that both Dr. David Green and Dr. Neil Shusterman have joined the RPS organization. Both individuals bring significant industry and drug development experience that will further enhance the depth and breadth of our clinical organizational leadership and expertise," said Harris Koffer, Pharm.D., President and Chief Operating Officer. "Under their leadership, I am confident that we will continue to expand our capabilities to provide innovative, global clinical development solutions to our customers."

David A. Green, Ph.D.

In his new role, Dr. Green will have oversight of Data Management, Statistics, Programming, Site Management and Monitoring, and Project Management.

Prior to joining RPS, Dr. Green held numerous positions of increasing scope and responsibility within the bio-pharmaceutical industry. Most recently, David served as Executive Director of Clinical Field Operations for Amgen, Inc. where he led the US Clinical Field Operations and oversaw field based trial operations across Phase I-III clinical trials and all therapeutic areas. During his tenure at Amgen he was also the Therapeutic Area Operations Lead for Diabetes/Obesity, Inflammation, and General Medicine.

David brings over 15 years of clinical trial operations experience in numerous therapeutic areas primarily associated with Oncology -- Supportive Care & Therapeutics, Diabetes/Obesity, Inflammation, General Medicine, Bone Metabolism, and HIV/AIDS. He brings extensive experience in the development and management of Clinical Field Operations, Clinical Trials Operations, and Clinical Drug Development in Phases I-III.

Neil H. Shusterman, M.D.

In his new role, Dr. Shusterman will have oversight of Medical, Regulatory Affairs, Medical Writing and Drug Safety Services.

Prior to joining RPS, Dr. Shusterman was Senior Vice President of Clinical Development at the Forest Research Institute of Forest Laboratories, Inc. At Forest Laboratories he also served as Senior Vice President, Clinical Development, Safety and Operations and Vice President, Internal Medicine Therapeutic Area, Clinical Development and Medical Affairs. Before joining Forest, Dr. Shusterman held the position of Vice President, Cardiovascular Therapeutic Area, North American Medical Affairs, R&D, at GlaxoSmithKline. He brings extensive knowledge and experience in clinical research and development, as well as therapeutic expertise in internal medicine, nephrology and cardiovascular medicine.

Additionally, Dr. Shusterman has served as an adjunct Assistant Professor in the Department of Medicine at the University of Pennsylvania's School of Medicine in Philadelphia, PA, and has held Administrative Appointments such as Chief Executive Officer, University of Pennsylvania Outpatient Dialysis Unit. He is board certified in Internal Medicine and Nephrology.

About RPS

RPS (ReSearch Pharmaceutical Services, Inc.), The Next Generation CRO, provides comprehensive global Phase I-IV clinical development solutions to the Pharmaceutical, Biotechnology and Medical Device industries. By combining an experienced clinical research operations infrastructure with the industry's largest resourcing engines, RPS is uniquely positioned to offer our clients both integrated and full service global outsourcing solutions.

SOURCE ReSearch Pharmaceutical Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Kellogg School of Management Expert Finds Multicultural Experience Enhances Creativity
2. Study by Texas A&M University-Corpus Christi Confirms Training With Vision Software Enhances Hitting Skills
3. New VP of Operations Enhances The Beryl Companies Leadership Team
4. CAS New SciFinder(R) Enhances the Research Experience Via the Web
5. Avista Capital Partners Enhances Energy Practice With Appointment of Gerhard Kurz
6. Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions
7. AT&T Enhances Performance for LAMMICO With Upgraded Network Services
8. Computer-Aided Detection in Screening Mammography Enhances Performance of a Single Reader
9. AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair
10. Technique enhances digital television viewing for visually-impaired
11. Z-shaped incision enhances minimally invasive surgery
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... District , the only authorized OSHA Training Institute Education Center headquartered in Northern ... protecting their workers from extreme heat at their worksites. Employers with workers ...
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology: